Novo Nordisk A S annual diluted eps
Diluted EPSBasic EPS
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S EPS History: Annual & Quarterly (NVO)
Novo Nordisk A S's diluted EPS was DKK 23.03 for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | DKK 23.03 | DKK 23.06 | DKK 0.40 | +1.77% |
| 2024 | 2024-12-31 | DKK 22.63 | DKK 22.67 | DKK 4.01 | +21.54% |
| 2023 | 2023-12-31 | DKK 18.62 | DKK 18.67 | DKK 6.40 | +52.37% |
| 2022 | 2022-12-31 | DKK 12.22 | DKK 12.26 | DKK 1.85 | +17.84% |
| 2021 | 2021-12-31 | DKK 10.37 | DKK 10.40 | DKK 1.36 | +15.16% |
| 2020 | 2020-12-31 | DKK 9.01 | DKK 9.03 | DKK 0.82 | +9.95% |
| 2019 | 2019-12-31 | DKK 8.19 | DKK 8.21 | — | — |
Novo Nordisk A S quarterly diluted eps
Diluted EPSBasic EPS
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | DKK 4.74 | DKK 4.74 | -DKK 1.22 | −20.47% |
| Q1 2026 | 2026-03-31 | DKK 10.91 | DKK 10.93 | — | — |
| Q4 2025 | 2025-12-31 | DKK 6.04 | DKK 6.06 | — | — |
| Q3 2025 | 2025-09-30 | DKK 4.50 | DKK 4.50 | — | — |
| Q2 2025 | 2025-06-30 | DKK 5.96 | DKK 5.96 | — | — |
Novo Nordisk A S diluted eps trends
Over the last five fiscal years, Novo Nordisk A S's diluted eps increased from DKK 9.01 to DKK 23.03, a change of DKK 14.03. The latest reported quarter, Q2 2026, shows DKK 4.74.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...